Error loading player: No playable sources found

4280

IBD Adverse Events Related to Therapy: Focus on Small Molecules

Date
May 20, 2024
This product is not available for individual purchase, but it is available as part of the following products:
Thumbnail for DDW 2024 - Full Program On Demand
Full DDW 2024 On Demand Program available now!

Loading...

Related Products

Thumbnail for IBD Controlled Trials II
IBD Controlled Trials II
SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented…
Thumbnail for IBD Diagnosis. Monitoring, and Prediction of Complications
IBD Diagnosis. Monitoring, and Prediction of Complications
SOCIETY: AGA This session highlights the latest research on novel prediction models in IBD as well as the role of the fecal microbiome and imaging in IBD…
Thumbnail for IMIBD Late Breakers and Innovations in IBD
IMIBD Late Breakers and Innovations in IBD
SOCIETY: AGA By popular demand, this new session highlights the best late-breakers submitted to the IBD section and well as innovations in technology and new paradigms of care in IBD
Thumbnail for Uncontrolled Therapeutic Observations in IBD
Uncontrolled Therapeutic Observations in IBD
SOCIETY: AGA In this session, several clinically relevant presentations will put the attendee at the cutting edge of research and clinical care, with regard to stem cells for perinal fistulas, biologic de-escalation, subcutaneous biologics, and use of small molecules in microscopic colitis